Meeting
2016 ASCO Annual Meeting
Neoadjuvant combination immunotherapy with ipilimumab (3 mg/kg or 10mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma.
Authors
Ahmad A. Tarhini
University of Pittsburgh Cancer Institute, Pittsburgh, PA
Ahmad A. Tarhini , Zahra Rahman , Yan Lin , Priyanka Vallabhaneni , Hussein Abdul-Hassan Tawbi , Andrew Gnan , Amanda McFadden , Amy Rose , Chelsea Pruckner , Melissa Wilson , James F. Pingpank Jr., Matthew Peter Holtzman , Robert L. Ferris , Uma N. M. Rao , John M. Kirkwood
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT01608594
Citation
J Clin Oncol 34, 2016 (suppl; abstr 9585)
DOI
10.1200/JCO.2016.34.15_suppl.9585
Abstract #
9585
Poster Bd #
190
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study of neoadjuvant combination immunotherapy in locally/regionally advanced melanoma.
First Author: Yana Najjar
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Neoadjuvant combination immunotherapy with pembrolizumab and high dose IFN-α2b in locally/regionally advanced melanoma.
First Author: Ahmad A. Tarhini
Poster
2012 ASCO Annual Meeting
Neoadjuvant ipilimumab in locally/regionally advanced melanoma: Clinical outcome and immune monitoring.
First Author: Ahmad A. Tarhini
Poster
2023 ASCO Annual Meeting
![<span>[</span><sup>18</sup><span>F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.</span>](https://d201v5jt9ylckg.cloudfront.net/299/15042/220219/220219_A3159_poster_pv.jpg)
[18F]FDG-PET to identify pathological responses upon neoadjuvant immune checkpoint blockade in cutaneous squamous cell carcinoma.
First Author: Sabine Breukers